Abstract
Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last decade, the therapeutic options for chronic progressive MS, both primary and secondary, are still limited. In order to find new pharmacological targets for the treatment of chronic progressive MS, the mechanisms of the underlying neurodegenerative process that becomes apparent as the disease progresses need to be elucidated. New animal models with prominent and widespread progressive degenerative components of MS have to be established to study both inflammatory and non-inflammatory mechanisms of neurodegeneration. Here, we discuss disease mechanisms and treatment strategies for chronic progressive MS.
Keywords: Multiple sclerosis, chronic progression, inflammation, neurodegeneration, treatment
Current Neuropharmacology
Title: Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Volume: 8 Issue: 3
Author(s): Dirk Fitzner and Mikael Simons
Affiliation:
Keywords: Multiple sclerosis, chronic progression, inflammation, neurodegeneration, treatment
Abstract: Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last decade, the therapeutic options for chronic progressive MS, both primary and secondary, are still limited. In order to find new pharmacological targets for the treatment of chronic progressive MS, the mechanisms of the underlying neurodegenerative process that becomes apparent as the disease progresses need to be elucidated. New animal models with prominent and widespread progressive degenerative components of MS have to be established to study both inflammatory and non-inflammatory mechanisms of neurodegeneration. Here, we discuss disease mechanisms and treatment strategies for chronic progressive MS.
Export Options
About this article
Cite this article as:
Fitzner Dirk and Simons Mikael, Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246218
DOI https://dx.doi.org/10.2174/157015910792246218 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Base Distribution in Dengue Nucleotide Sequences Differs Significantly from Other Mosquito-Borne Human-Infecting Flavivirus Members
Current Computer-Aided Drug Design Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms
Current Pharmaceutical Design Microbial Sensors Based on Nanostructures
Recent Patents on Nanomedicine Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Recent Advances in the Molecular Biology of West Nile Virus
Current Molecular Medicine Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment
CNS & Neurological Disorders - Drug Targets Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research The Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Infectious Disorders - Drug Targets Substance Abuse, HIV-1 and Hepatitis
Current HIV Research The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Optimization of Spotting Buffer for Polystyrene Based ELISA Arrays
Current Analytical Chemistry